Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Andes1537 For Injection

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (2)
Phase 1/2 (1)

Trial Status

Completed1
Terminated1
Unknown1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT02428712Phase 1/2CompletedPrimary

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

NCT04894825Phase 1UnknownPrimary

Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

NCT02508441Phase 1TerminatedPrimary

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

Showing all 3 trials

Research Network

Common Treatments

  • Andes1537 For Injection1
  • Fore83941
  • M1081

Active Sponsors

  • Fore Biotherapeutics1
  • Andes Biotechnologies1
  • FutureGen Biopharmaceutical (Beijing) Co., Ltd1

Top Investigators

Related Conditions

  • Brafmutated Tumors1

Activity Timeline